Stevanato Group (STVN) 46th Annual William Blair Growth Stock Conference summary
Event summary combining transcript, slides, and related documents.
46th Annual William Blair Growth Stock Conference summary
2 Jun, 2026Company overview and strategic positioning
Over 75 years of history, specializing in glass containers for the pharmaceutical industry, with a mission-critical role in biopharma supply chains.
Achieved steady double-digit growth, expanding from €18 million in 2000 to a guided €1.3 billion in 2025 revenue, with EBITDA consistently above 25%.
Market leader in cartridges and ready-to-use vials, and second globally in syringes, focusing on partnerships with the top 25 pharma companies.
Emphasizes end-to-end value proposition, offering primary packaging, drug delivery systems, and engineering solutions.
Maintains a global manufacturing footprint with 13 sites in nine countries, ensuring consistent quality and supply chain reliability.
Product innovation and R&D
Developed proprietary EZ-fill technology for syringes, cartridges, and vials, supported by a robust IP portfolio.
R&D centers in Italy and Boston enable early-stage collaboration with pharma clients, tailoring products for phase II/III and commercial launches.
Focused on high-value products such as auto-injectors and pens, addressing the shift toward self-medication and biologics.
Ongoing investments in sophisticated coatings and large-volume devices to meet rising demand in the biologics sector.
M&A activity targets specialized competencies to enhance the product portfolio.
Capacity expansion and capital allocation
Major investments post-IPO, including over €500 million in a new Fishers, Indiana facility and expanded capacity in Italy and Germany.
70% of $1.2 billion IPO proceeds reinvested to support extraordinary CapEx cycles and global capacity growth.
Plans to reduce CapEx to 10%-12% of revenue by 2027, aiming to generate significant free cash flow.
Flexible manufacturing allows rapid adaptation between syringes and cartridges to match market shifts.
Greenfield plants mirror customer supply chains, supporting global pharma partners with consistent quality.
Latest events from Stevanato Group
- Q2 2026 revenue up 8% with margin gains, led by high-value solutions and strategic divestiture.STVN
Q2 20266 Aug 2026 - Revenue up 2% in Q3 2024, but margins and profit pressured by higher costs and destocking.STVN
Q3 20249 Jul 2026 - Q1 2025 revenue up 9% to €256.6M, with margin and free cash flow gains; 2025 outlook reaffirmed.STVN
Q1 20259 Jul 2026 - Q1 2026 revenue rose 10% at constant currency, with margin gains and guidance reaffirmed.STVN
Q1 20268 Jul 2026 - Strong growth in high-value pharma solutions, capacity expansion, and global integration drive outlook.STVN
Jefferies London Healthcare Conference 20258 Jul 2026 - High-value ready-to-fill products and innovation drive growth and margin expansion.STVN
Jefferies Global Healthcare Conference 20265 Jun 2026 - High-value solutions and biologics drive robust growth, with expanding margins and global investments.STVN
Investor presentation4 Jun 2026 - High-value solutions and capacity expansion fuel robust growth and margin gains through 2027.STVN
Bank of America Global Healthcare Conference 202612 May 2026 - FY25 revenue hit €1,186M with HVS at 46%; FY26 guidance targets up to €1.29B revenue.STVN
Investor presentation25 Mar 2026